Infinity Regains Pipeline Rights, Gives Up Equity In Rejiggered Purdue Alliance
This article was originally published in The Pink Sheet Daily
Executive Summary
Infinity avoids the erosion of its rights to a promising PI3K drug by restructuring its alliance with Purdue and Mundipharma, essentially returning all control back to the cancer drug developer.